Strategic Inhibition of CHRM Autoantibodies: Molecular Insights and Therapeutic Potentials in Long COVID

Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 21, 2025

In addition to the conventional symptoms reported for COVID-19, it is becoming increasingly clear that patients with long COVID are exhibiting new due emergence of autoantibodies against G-protein-coupled receptors, among which human muscarinic cholinergic receptors (CHRMs) have been prominently reported. With a chronic condition such as COVID, additional caused by anti-CHRM (AAbs) proven be an added burden on these patients. The origins AAbs, their interactions with, and effects function neural non-neural cells within nervous system remained unknown. Furthermore, specific symptom complex they contribute has not clearly understood. this context, we address issues here suggest methods combat neurological in COVID.

Language: Английский

---

Serotonergic psychedelics as potential therapeutics for post-COVID-19 syndrome (or Long COVID): A comprehensive review

Progress in Neuro-Psychopharmacology and Biological Psychiatry, Journal Year: 2025, Volume and Issue: unknown, P. 111279 - 111279

Published: Feb. 1, 2025

Language: Английский

---

Persistent Symptoms and Associated Risk Factors of COVID-19: A Cross-Sectional Study in Minia, Upper Egypt

Healthcare, Journal Year: 2025, Volume and Issue: 13(7), P. 699 - 699

Published: March 22, 2025

Background: A significant number of COVID-19 survivors around the world have been reporting persistent symptoms following their recovery. Long COVID is recognized as a condition affecting not only respiratory but also gastrointestinal, cardiovascular, neurological, immune, and hematopoietic systems. Objective: This study aimed to describe in six months post-infection Minia, Upper Egypt, investigate associated risk factors. Methods: observational cross-sectional included 189 hospitalized non-hospitalized patients previously diagnosed with COVID-19. Demographic data, symptom severity, comorbidities, were collected. logistic regression analysis was used identify factors long COVID, statistical significance set at p < 0.05. Results: In total, 68.8% participants women, 83.5% reported least one ongoing symptom. The most self-reported fatigue (73.5%) myalgia (45.5%), followed by dyspnea (43.3%). Age an increased developing (OR 1.028, 95% CI 1.003-1.054, = 0.030). Patients who during acute phase had more than twice risks having 2.384, 1.055-5.387, 0.037). Conclusions: substantial proportion continues experience symptoms, primarily constitutional neurological manifestations. Many self-medicating unprescribed antibiotics, highlighting need for public awareness regarding viral infections improper antibiotic use.

Language: Английский

---

A Real-Life Study in Patients Newly Diagnosed with Autoimmune Hashimoto’s Thyroiditis: Analysis of Asthenia as Admission Complaint

Life, Journal Year: 2024, Volume and Issue: 14(11), P. 1380 - 1380

Published: Oct. 27, 2024

Background: Amid the large panel of autoimmune thyroid diseases, Hashimoto’s thyroiditis (HT) represents a major point across multidisciplinary daily practice. When it comes to clinical picture, particularly in regard asthenia (also described as “fatigue” or “decreased energy”), differential diagnosis is challenging, and meticulous anamnesis should be backed up by focused lab investigations. Our objective was analyze newly diagnosed patients with HT relationship presence an admission complaint. Methods: This retrospective, multi-centric, real-life study conducted secondary endocrine units (university hospitals) from July 2022 2023. The exclusion criteria were COVID-19 infection; active malignancy, etc. Results: cohort (N = 120) included group (AS, 49.2%) non-AS similar age (49.3 ± 14.7 vs. 47.1 14.8 y, p 0.426). Headache more frequent AS (35.6% 18%, 0.03). Thyroid function HT-related antibodies assays between groups show no correlation serum total cholesterol triglycerides, respectively. TSH levels did not vary among sub-groups (p 0.701). One third studied population affected hypothyroidism (TSH > 4.5 μIU/mL), being seen at higher rate (39%) (23%). Total positively correlated patients’ (r 0.180, 0.049) triglycerides 120; r 0.324, < 0.001), found only 0.246, 0.006, respectively, 0.319, 0.001). Conclusions: analysis pinpointed fact that, practice, complaint seems less indicator underlying dysfunction level against without full picture thyrotoxicosis myxoedema.

Language: Английский

---

Aktueller Stand der Long/Post-COVID-Therapie

Deleted Journal, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 18, 2024

Die Folgen einer SARS-CoV-2("severe acute respiratory syndrome coronavirus 2")-Infektion können die Lebensqualität der Betroffenen durch Symptome wie chronische Fatigue, Belastungsintoleranz, Dyspnoe und kognitive Dysfunktion stark beeinträchtigen. Dabei stellt Komplexität des Post-COVID("coronavirus disease")-Syndroms eine große klinische Herausforderung dar, nicht nur bezüglich Eingrenzung pathophysiologischen Grundlagen, sondern auch im Hinblick auf Einleitung gezielter wirksamer Therapien. Aufgrund hohen Leidensdrucks werden in Ermangelung therapeutischer Alternativen verschiedene Verfahren Plasmapherese, Lipoproteinapherese Immunadsorption eingesetzt, um Fatigue Belastungsintoleranz zu lindern. Wirksamkeit dieser ist jedoch beim Post-COVID-Syndrom noch ausreichend untersucht. derzeit laufenden randomisierten, placebokontrollierten Studien zielen darauf ab, Wirkung von Immunadsorptionsbehandlungen andere Parameter untersuchen sowie Marker für das Ansprechen Behandlung identifizieren.

---